Non-standard abbreviations: dAb -single domain antibody; DD -death domain; FLfull-length; PTX3 -pentraxin-3; TNFR1 -TNF receptor-1; sTNFR1 -soluble TNF receptor-1; TNFRSF1A -TNF receptor superfamily 1A gene; TRAPS -TNF receptor associated periodic syndrome.
TNFR1 [1] . TRAPS involves stimulation of inflammation by misfolding of mutated TNFR1 causing TNF-independent signalling by intra-cellular, aggregated mutant TNFR1 and/or an unfolded protein response and stimulation of ROS production [2] [3] [4] [5] [6] [7] [8] [9] [10] . However, studies in mutant TNFR1 knock-in mice showed the TRAPS-like phenotype to be associated with the mutant/WT TNFR1 heterozygous state (as is also the case in TRAPS patients) and not with mutant/mutant homozygosity [7] . This indicates that synergy between TNF-independent effects of intra-cellular mutant TNFR1 and TNF-dependent signalling by cell-surface WT receptor are necessary to generate the full TRAPS phenotype.
TRAPS is associated with both 'structural' and 'non-structural' TNFR1
variants [7] . The former inevitably generate TRAPS and involve amino acid substitutions with significant structural consequences; these include cysteine mutations that disrupt disulphide bond formation (e.g. C33Y), and non-cysteine mutations (e.g. T50M); these mutations result in intra-cellular retention and reduced TNF-binding capacity, which is most profound in the cysteine mutants. Nonstructural variants are R92Q and P46L, which occur in 1-10% of the general population as well as in TRAPS patients; these variants show cell-surface expression and TNF binding capacity similar to WT-TNFR1 and generate a relatively mild clinical phenotype.
In order to investigate the contribution of cell-surface TNFR1 to the TRAPS phenotype, we have employed an anti-human TNFR1 single domain antibody (dAb; DMS5541) that neutralises activation of TNFR1 by TNF without inhibiting TNF-TNFR1 interaction [11]; a similar anti-mouse TNFR1 dAb has also been reported [12] .
This demonstrates both TNF-dependent and independent aspects of cytokine production associated with TRAPS, but with different contributions dependent on cell type, TNFR1 mutation and cytokine produced. 
Results and discussion
The anti-TNFR1 dAb binds to HEK-293 cell surface WT and variant TNFR1.
HEK-293 cells transfected with full-length (FL) WT or TRAPS-associated variants of
TNFRSF1A under doxycycline control [2, 4, 13] were cultured with or without doxycycline to induce expression of the recombinant TNFR1. Figure 1a and b show cell-surface binding of anti-TNFR1 mAb (mAb225) and dAb (DMS5541), with nonspecific staining subtracted in each case. As reported previously [2] , surface expression of TNFR1 was very low in the HEK-293 transfectants not treated with doxycycline (i.e. 'non-induced') ( compared to the directly phycoerythrin-labelled mAb (Fig. 1a) .)
HEK-293 cells transfected with the R347A mutant of WT or TRAPSassociated variants of TNFRSF1A under doxycycline control were employed, as in our previous studies [4] . The R347A substitution inactivates the death domain (DD) in the cytoplasmic region of TNFR1. This inhibits signalling via the DD (including DD-dependent induction of apoptosis); it also reduces the normal intra-cellular accumulation of TNFR1 that is DD-dependent [4] . Thus, as expected, doxycycline induction of the R347A transfectants led to very much higher cell-surface expression of WT, R92Q and P46L TNFR1 (Fig. 1d) ; cell-surface expression of the T50M structural mutant was also detectable, and cell-surface C33Y increased only slightly, which is consistent with our previous report that structural mutants of TNFR1 with the R347A substitution are largely retained in the cytoplasm of HEK-293 cells, even following doxycyclin induction [4] . In all cases, both the anti-TNFR1 dAb and mAb bound to a similar extent, indicating that the dAb binds to structural and nonstructural variants of TNFR1, as well as to the WT. In the absence of TNF, the non-induced R92Q and T50M FL-TNFR1 transfectants showed slight, but significant, elevation of IL-8 production compared to WT transfectants; this appeared to be TNF-independent as there was no significant inhibition by the anti-TNFR1 dAb (DMS5541) relative to the non-specific control dAb (DMS5556) (Fig. 1e) . Very similar results were obtained for IL-8 production by the non-induced R347A-TNFR1 transfectants in the absence of TNF, with the R92Q and T50M variants enhancing IL-8 production significantly and without significant inhibition of this by the anti-TNFR1 dAb (Fig. 1g ).
When the non-induced HEK-293 FL TNFR1 transfectants were treated with 3ng/ml TNF, IL-8 production was greatly augmented (> 10-fold) for all TNFR1 variants, although the highest IL-8 production was given by the WT transfectant ( Fig.   1f ). In all cases, the anti-TNFR1 dAb caused very significant inhibition of IL-8 production, indicating that it was highly dependent on TNF signalling via TNFR1 (Fig. 1f) . Interestingly, the non-induced R347A-TNFR1 transfectants behaved differently from the FL-TNFR1 transfectants when treated with 3ng/ml TNF (Fig. 1h) -lower levels of IL-8 were produced by the WT and non-structural TNFR1 variants (R92Q and P46L) whereas significantly higher levels were produced by the C33Y and T50M structural variants (Fig. 1h) . In all cases, the anti-TNFR1 dAb again inhibited (Fig. 2e) . As mentioned previously, the higher staining by the dAb relative to the mAb is explained by the signal amplification given by the biotinylated-dAb/ Streptavidin-Alexa Fluor 647 compared to the directly phycoerythrin-labelled mAb (Fig. 2e) . Fig. 3a) and CCL2 ( Fig.   3c ) relative to the WT transfectant; T50M gave significantly enhanced production of G-CSF (Fig. 3e) and both R92Q and T50M significantly enhanced PTX-3 production (Fig. 3g) relative to WT; only P46L gave enhanced CCL-5 (Fig. 3i) ; more IL-6 was produced by the WT and non-structural variants than the structural variants (Fig. 3k) .
In none of these cases did anti-TNFR1 dAb significantly inhibit the cytokine production, indicating this to be independent of stimulation, or clustering, of cellsurface TNFR1 in the absence of TNF.
Stimulation of the SK-Hep-1 transfectants with 1ng/ml TNF induced moderately higher production of all cytokines. In particular, both R92Q and T50M transfectants produced significantly higher levels than WT of IL-8 (Fig. 3b ) and G-CSF (Fig. 3f) ; P46L also enhanced production of G-CSF (Fig. 3f) , and only P46L induced higher levels of CCL-5 (Fig. 3j) ; the spread of replicate values for CCL-2 ( Fig. 3d) and PTX3 (Fig. 3h ) meant that no differences were significant, and no TNFR1 variant transfectants produced higher levels of IL-6 than did the WT transfectant (Fig. 3l) . In many instances, the production of cytokines was significantly inhibited by the anti-TNFR1 dAb, indicating its dependency on cellsurface TNFR1 activation by TNF. Further increases in cytokine production were observed when the cells were treated with 3ng/ml TNF (which was also significantly inhibited by anti-TNFR1 dAb), indicating a TNF dosage effect (data not shown).
Thus, different TNFR1 variants differentially enhanced the production of particular cytokines in both TNF-independent and TNF-dependent ways.
Concluding remarks
Both structural and non-structural TRAPS-associated TNFR1 variants enhance cytokine production by both TNF-independent and TNF-dependent mechanisms. The TNF-dependent mechanism requires cell-surface expression of TNFR1, as this can be blocked by the TNFR1-specific dAb. The observation that the anti-TNFR1 dAb does not affect the stimulation of cytokine production by TNFR1 variants in the absence of exogenously added TNF (although the dAb can bind to these variants) is consistent with a TNF-independent component of stimulation that involves intra-cellular TNFR1. [7, 13] .
In the SK-Hep-1 transfectants, different TNFR1 variants affected the production of different cytokines. No enhancement of cytokine production was induced by the C33Y FL-TNFR1 mutant, although we showed previously that doxycycline-induced C33Y FL-TNFR1 SK-Hep-1 transfectants produce higher levels of G-CSF, GM-CSF, CCL-2 and PTX3 than both the WT and the R92Q and T50M transfectants [6] . Thus, the effect of this cysteine mutation on cytokine production may be much more dependent on its level of intra-cellular expression than upon synergy with exogenous TNF. Interestingly, TNF stimulation led to significantly increased IL-8 and G-CSF, for the R92Q and T50M mutants, and G-CSF and CCL-5 for P46L, when compared to WT. This would suggest an increased sensitivity to extra-cellular TNF in these mutants, as this augmented response is inhibited by the anti-TNFR1 dAb.
The dAb inhibited TNF-stimulated cytokine production only to the level observed in the absence of TNF stimulation; this suggests that the ligand-independent component of cytokine production induced by e.g. the R92Q TNFR1 variant is not driven solely by changes to extracellular receptor clustering [14] .
Our findings are consistent with Simon et al. [7] , indicating synergy between variant and WT TNFR1 in generating the full TRAPS phenotype, and their proposal that expression of TRAPS-associated TNFR1 variants confers hypersensitivity to external inflammatory stimuli [7] . This might explain why TRAPS patients experience recurrent flares rather than unremitting inflammation -the baseline level of ligand-independent signalling by variant TNFR1 alone might not generate clinically overt symptoms, but a very small external inflammatory stimulus, which would normally be below the threshold to generate an obvious effect, leads to exaggerated signalling that induces the flare.
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